The Abu Dhabi Investment Authority (ADIA), along with London-based private equity fund HarbourVest, is in discussions to acquire a minority stake in Cohance Lifesciences, a Hyderabad-based pharmaceuticals platform owned by global PE fund Advent International. The investors are looking to invest $350-400 million for a significant minority stake, valuing Cohance Lifesciences at about $1.5 billion, according to sources. Advent International currently owns a 76% stake in Suven Pharmaceuticals, which was merged with Cohance Lifesciences. ADIA already owns a stake in Intas Pharmaceuticals. With assets under management worth $850 billion, ADIA has made several investments in India since 2018.